Status:

RECRUITING

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

Lead Sponsor:

Qurient Co., Ltd.

Conditions:

Chronic Graft-Versus-Host Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chron...

Eligibility Criteria

Inclusion

  • Subjects who are allogeneic HSCT recipients with moderate or severe active cGVHD requiring systemic immune suppression.
  • Subjects with relapsed or refractory active cGVHD who have progressed after all available standard of care treatments.
  • Subject must have documented progressive disease as defined by the NIH 2014 consensus criteria, in terms of either organ specific algorithm or global assessment, or active, symptomatic cGVHD for which the treating physician believes that a new line of systemic therapy is required.
  • Adequate organ and bone marrow functions.
  • Karnofsky Performance Scale of ≥ 60.

Exclusion

  • Exposure to CSF1R inhibitor therapy for any indication after allogeneic transplant.
  • Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer.
  • Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of enrollment.
  • Female subject who is pregnant or breastfeeding.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

Key Trial Info

Start Date :

December 23 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2029

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT07138196

Start Date

December 23 2025

End Date

October 31 2029

Last Update

December 30 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Hospital Clinic de Barcelona

Barcelona, Spain

2

Hospital General Universitario Gregorio Maranon

Madrid, Spain

3

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Spain

4

Hospital Universitario Virgen de la Arrixaca

Murcia, Spain

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease | DecenTrialz